RPL17 and metastatic melanoma: In the SGN35-033 phase II trial, BV was combined with pembrolizumab, the PD-1 inhibitor, among patients with metastatic NSCLC (mNSCLC) or metastatic melanoma previously treated with PD-1 inhibitors.